Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H23Cl2N3OS |
Molecular Weight | 448.409 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)C2=C(\C=C3/SCCN(C3=O)C4=CC=C(Cl)C(Cl)=C4)C=CC=C2
InChI
InChIKey=LHYMPSWMHXUWSK-STZFKDTASA-N
InChI=1S/C22H23Cl2N3OS/c1-25-8-10-26(11-9-25)20-5-3-2-4-16(20)14-21-22(28)27(12-13-29-21)17-6-7-18(23)19(24)15-17/h2-7,14-15H,8-13H2,1H3/b21-14-
Molecular Formula | C22H23Cl2N3OS |
Molecular Weight | 448.409 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Elzasonan (CP 448187) is a serotonin 1B/1D receptor antagonist. Elzasonan was primarily metabolized via oxidative N‐demethylation, N‐oxidation, and aryl hydroxylation. Pfizer was developing elzasonan for the treatment of anxiety and affective disorders however development has been discontinued.
CNS Activity
Originator
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:02:05 GMT 2025
by
admin
on
Mon Mar 31 18:02:05 GMT 2025
|
Record UNII |
933PJL964R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66885
Created by
admin on Mon Mar 31 18:02:05 GMT 2025 , Edited by admin on Mon Mar 31 18:02:05 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID7047277
Created by
admin on Mon Mar 31 18:02:05 GMT 2025 , Edited by admin on Mon Mar 31 18:02:05 GMT 2025
|
PRIMARY | |||
|
933PJL964R
Created by
admin on Mon Mar 31 18:02:05 GMT 2025 , Edited by admin on Mon Mar 31 18:02:05 GMT 2025
|
PRIMARY | |||
|
205683-28-9
Created by
admin on Mon Mar 31 18:02:05 GMT 2025 , Edited by admin on Mon Mar 31 18:02:05 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
6914152
Created by
admin on Mon Mar 31 18:02:05 GMT 2025 , Edited by admin on Mon Mar 31 18:02:05 GMT 2025
|
PRIMARY | |||
|
C556408
Created by
admin on Mon Mar 31 18:02:05 GMT 2025 , Edited by admin on Mon Mar 31 18:02:05 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110932
Created by
admin on Mon Mar 31 18:02:05 GMT 2025 , Edited by admin on Mon Mar 31 18:02:05 GMT 2025
|
PRIMARY | |||
|
C72755
Created by
admin on Mon Mar 31 18:02:05 GMT 2025 , Edited by admin on Mon Mar 31 18:02:05 GMT 2025
|
PRIMARY | |||
|
361343-19-3
Created by
admin on Mon Mar 31 18:02:05 GMT 2025 , Edited by admin on Mon Mar 31 18:02:05 GMT 2025
|
PRIMARY | |||
|
8240
Created by
admin on Mon Mar 31 18:02:05 GMT 2025 , Edited by admin on Mon Mar 31 18:02:05 GMT 2025
|
PRIMARY | |||
|
300000036934
Created by
admin on Mon Mar 31 18:02:05 GMT 2025 , Edited by admin on Mon Mar 31 18:02:05 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET->ANTAGONIST | |||
|
SALT/SOLVATE -> PARENT | |||
|
EXCRETED UNCHANGED |
FECAL
|
||
|
EXCRETED UNCHANGED |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
M6 accounted (average of six human subjects) for 5.6% (sum of M5 and M6) of the administered dose in feces
FECAL
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
sum of M5 and M6 counted for 5.6% of the administered dose in feces
FECAL
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||